Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2013 Aug;9(8):761-72. doi: 10.1586/1744666X.2013.816479.

B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress.

Author information

1
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK.

Abstract

B cells play a central role in the pathogenesis of systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody-associated vasculitis. There are various strategies for targeting B cells including depletion, inhibition of survival factors, activation and inhibition of co-stimulatory molecules. Controlled trials in systemic lupus erythematosus have shown positive results for belimumab, promising results for epratuzumab and negative results for rituximab. The failure of rituximab in controlled trials has been attributed to trial design, sample size and outcome measures rather than true inefficacy. In anti-neutrophil cytoplasmic antibody-associated vasculitis, rituximab is effective for remission induction and in relapsing disease. However, the optimal long-term re-treatment strategy remains to be determined. Over the next 5 years, evidence will be available regarding the clinical efficacy of these novel therapies, biomarkers and their long-term safety.

PMID:
23971754
DOI:
10.1586/1744666X.2013.816479
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for White Rose Research Online
Loading ...
Support Center